Explain this page
Arphra AIPlain-English read on AbbVie Inc.’s valuation06-03today
- AbbVie Stock Will Hit $300 on This Date5h
- Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Bet8h
- Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance11h
- Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance11h
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$1,650.66
+645.69% vs spot
Recommendation
Strong Buy
15 of 17 methods
Method spread
5bull10bear
±5% threshold
Analyst PT consensus: $257.54 (+16.34%)
Candlestick · 1Y
Open in chart workstation →ABBV
221.59+16.10%H 244.81L 181.73MA50 210.77MA200 220.34Avg vol 6.2M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.09% | -2.04% | +5.23% | -0.03% | -1.02% | -3.11% | +16.00% | +59.69% | +91.63% | +263.53% | +532.54% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$34.15M
10 txns
Net flow
−$34.15M
Aftermarket
LiveLast trade
$221.40
8 sh
Bid
$221.36
2 sh
Ask
$221.41
18 sh
Spread
$0.050
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $15B | $699M | $0.39 |
| Q4 Dec 2025 | $16.62B | $1.82B | $1.02 |
| Q3 Sep 2025 | $15.78B | $186M | $0.10 |
| Q2 Jun 2025 | $15.42B | $938M | $0.53 |
| Q1 Mar 2025 | $13.34B | $1.29B | $0.72 |
| Q4 Dec 2024 | $15.1B | -$22M | $-0.02 |
Sector & industry today
LiveSectors
- Utilities+1.26%
- Industrials+0.95%
- Basic Materials+0.55%
- Consumer Cyclical+0.45%
- Consumer Defensive+0.14%
- Energy+0.00%
- Financial Services-0.44%
- Real Estate-0.50%
- Healthcare-0.58%
- Technology-1.07%
- Communication Services-1.63%
Top industries (issuer's industry highlighted)
- Drug Manufacturers - General-0.71%
- Electronic Gaming & Multimedia+5.54%
- Independent Power Producers+3.63%
- Communication Equipment-3.37%
- Medical - Equipment & Services+2.84%
- Broadcasting-2.65%
- Internet Content & Information-2.47%
- Hardware, Equipment & Parts-2.46%
- Trucking-2.34%
- Conglomerates+2.16%
- Oil & Gas Drilling-2.16%
- Financial - Mortgages+1.99%
Analyst view
DB · price_targets + analyst_gradesConsensus target
$257.54
+16.34% upside
Low
$223.00
Median
$260.00
High
$298.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- AbbVie Stock Will Hit $300 on This Date247wallst.com·Jun 16, 2026
- Brokers Suggest Investing in AbbVie (ABBV): Read This Before Placing a Betzacks.com·Jun 16, 2026
- Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearanceprnewswire.com·Jun 16, 2026
- Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearanceprnewswire.com·Jun 16, 2026
- 3 High-Yield Dividend Stocks to Buy Hand Over Fist in Junefool.com·Jun 15, 2026
- AbbVie (ABBV) Rises Higher Than Market: Key Factszacks.com·Jun 12, 2026
- AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.fool.com·Jun 12, 2026
- AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Resultsprnewswire.com·Jun 12, 2026
Peers
Total assets
$133.96B
Total debt
$69.07B
Cash & equiv
$5.23B
Operating CF
$19.03B
Free cash flow
$17.82B
Buybacks
-$980M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Purdue David Ryan officer: SVP, Controller | Sell | 5,230 | $1.22M | Mar 04, 2026 |
Siatis Perry C officer: EVP, GC AND SECRETARY | Sell | 5,777 | $1.35M | Mar 02, 2026 |
Siatis Perry C officer: EVP, GC AND SECRETARY | Sell | 2,600 | $611.68K | Mar 02, 2026 |
Siatis Perry C officer: EVP, GC AND SECRETARY | Sell | 10,291 | $2.41M | Mar 02, 2026 |
Siatis Perry C officer: EVP, GC AND SECRETARY | Sell | 22,381 | $5.15M | Feb 25, 2026 |
SALEKI-GERHARDT AZITA officer: EVP, CHIEF OPERATIONS OFFICER | Sell | 42,370 | $8.41M | Aug 12, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $61.16B | $20.09B | $4.23B | $2.37 | +6.91% |
| FY 2024 | $56.33B | $9.14B | $4.28B | $2.39 | +7.59% |
| FY 2023 | $54.32B | $12.76B | $4.86B | $2.72 | +8.95% |
| FY 2022 | $58.05B | $18.12B | $11.84B | $6.63 | +20.39% |
| FY 2021 | $56.2B | $17.92B | $11.54B | $6.45 | +20.54% |